240 related articles for article (PubMed ID: 35672853)
21. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
[TBL] [Abstract][Full Text] [Related]
22. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
Facha W; Tadesse T; Wolka E; Astatkie A
PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
[TBL] [Abstract][Full Text] [Related]
23. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
Mmasa KN; Powis K; Sun S; Makhema J; Mmalane M; Kgole S; Masasa G; Moyo S; Gerschenson M; Mohammed T; Legbedze J; Abrams EJ; Kurland IJ; Geffner ME; Jao J
HIV Med; 2021 Sep; 22(8):715-722. PubMed ID: 34003565
[TBL] [Abstract][Full Text] [Related]
24. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
25. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
[TBL] [Abstract][Full Text] [Related]
26. Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA; Protopopescu C; Mpoudi-Etame M; Omgba Bassega P; Maradan G; Olinga J; Varloteaux M; Tovar-Sanchez T; Delaporte É; Kouanfack C; Boyer S;
J Acquir Immune Defic Syndr; 2023 Nov; 94(3):262-272. PubMed ID: 37851566
[TBL] [Abstract][Full Text] [Related]
27. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
[TBL] [Abstract][Full Text] [Related]
28. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
[TBL] [Abstract][Full Text] [Related]
29. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.
Griesel R; Banda CG; Zhao Y; Omar Z; Wiesner L; Meintjes G; Sinxadi P; Maartens G
J Acquir Immune Defic Syndr; 2024 May; 96(1):85-91. PubMed ID: 38372621
[TBL] [Abstract][Full Text] [Related]
31. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
Romo ML; Brazier E; Mahambou-Nsondé D; De Waal R; Sekaggya-Wiltshire C; Chimbetete C; Muyindike WR; Murenzi G; Kunzekwenyika C; Tiendrebeogo T; Muhairwe JA; Lelo P; Dzudie A; Twizere C; Rafael I; Ezechi OC; Diero L; Yotebieng M; Fenner L; Wools-Kaloustian KK; Shah NS; Nash D;
J Int AIDS Soc; 2022 Jul; 25(7):e25961. PubMed ID: 35848120
[TBL] [Abstract][Full Text] [Related]
32. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P; Lugemwa A; Wynne B; Mujuru HA; Violari A; Kityo CM; Archary M; Variava E; White E; Turner RM; Shakeshaft C; Ali S; Nathoo KJ; Atwine L; Liberty A; Bbuye D; Kaudha E; Mngqibisa R; Mosala M; Mumbiro V; Nanduudu A; Ankunda R; Maseko L; Kekitiinwa AR; Giaquinto C; Rojo P; Gibb DM; Turkova A; Ford D;
Lancet HIV; 2022 Sep; 9(9):e638-e648. PubMed ID: 36055295
[TBL] [Abstract][Full Text] [Related]
33. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
[TBL] [Abstract][Full Text] [Related]
34. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
36. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA; Nishimwe ML; Tovar-Sanchez T; Lantche Wandji M; Mpoudi-Etame M; Maradan G; Omgba Bassega P; Varloteaux M; Montoyo A; Kouanfack C; Delaporte E; Boyer S;
Pharmacoeconomics; 2021 Mar; 39(3):331-343. PubMed ID: 33355914
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
Bollen P; Freriksen J; Konopnicki D; Weizsäcker K; Hidalgo Tenorio C; Moltó J; Taylor G; Alba-Alejandre I; van Crevel R; Colbers A; Burger D;
Clin Infect Dis; 2021 Jan; 72(1):121-127. PubMed ID: 32103260
[TBL] [Abstract][Full Text] [Related]
38. Gestational weight gain and adverse birth outcomes in South African women with HIV on antiretroviral therapy and without HIV: a prospective cohort study.
Madlala HP; Myer L; Jao J; Geffen H; Matjila M; Fisher A; Meyer D; Werner EF; Petro G; Cu-Uvin S; McGarvey ST; Bengtson AM
J Int AIDS Soc; 2024 Jun; 27(6):e26313. PubMed ID: 38926935
[TBL] [Abstract][Full Text] [Related]
39. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
[TBL] [Abstract][Full Text] [Related]
40. Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France.
Kherabi Y; de Castro N; Sellier PO; Hamet G; Brun A; Méchaï F; Joly V; Yazdanpanah Y; Molina JM
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):85-90. PubMed ID: 35616997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
